SG Americas Securities
PRLD icon

SG Americas Securities’s Prelude Therapeutics PRLD Stock Holding History

SG Americas Securities’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,251
Closed -$13K – 3453
2025
Q1 		$13K Buy
+17,251
New +$16.1K ﹤0.01% 3402
2024
Q1 		– Sell
-13,100
Closed -$56K – 3343
2023
Q4 		$56K Buy
+13,100
New +$39.9K ﹤0.01% 2901
2021
Q4 		– Sell
-8,691
Closed -$272K – 3726
2021
Q3 		$272K Buy
+8,691
New +$281K ﹤0.01% 3016

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

SG Americas Securities's PRLD Position: Q2 2025 in Review

SG Americas Securities sold out of Prelude Therapeutics (PRLD) in Q2 2025, closing a stake of 17,251 shares — an estimated $13K sold.

SG Americas Securities first reported a position in PRLD in Q3 2021 and held it in 3 quarters. The position peaked at $272K in Q3 2021. 50 funds tracked by Wall St. Rank hold PRLD as of Q2 2025.

  • SG Americas Securities reported no remaining Prelude Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 17,251 Prelude Therapeutics shares in Q2 2025, an estimated $13K.
  • SG Americas Securities first reported a position in Prelude Therapeutics in Q3 2021 and held it in 3 quarters.
  • SG Americas Securities's Prelude Therapeutics position peaked at $272K in Q3 2021.
  • 50 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.